GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2006-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00382512
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00381810
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research, Pllc, Paradise Valley, Arizona, United States
🇺🇸Eden Medical Center San Leandro Hospital, San Leandro, California, United States
🇺🇸Intermountain Research Center, Boise, Idaho, United States
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00382148
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 853
- Registration Number
- NCT00379795
An Observational Study of the Use and Safety of Xolair® During Pregnancy
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT00373061
- Locations
- 🇺🇸
Ppd Development, Llc, Morrisville, North Carolina, United States
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT00351767
A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 167
- Registration Number
- NCT00345163
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT00338143
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00337883
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00336973
© Copyright 2024. All Rights Reserved by MedPath